NFE2L1 and NFE2L3 Complementarily Maintain Basal Proteasome Activity in Cancer Cells Through CPEB3-Mediated Translational Repression

Overview

Journal Mol Cell Biol

Specialty Cell Biology

Date 2020 May 6

PMID 32366381

Citations 26

Authors

Tsuyoshi Waku

Hiroyuki Katayama

Miyako Hiraoka

Atsushi Hatanaka

Nanami Nakamura

Yuya Tanaka

Natsuko Tamura

Akira Watanabe

Akira Kobayashi

Affiliations

Soon will be listed here.

Abstract

Proteasomes are protease complexes essential for cellular homeostasis, and their activity is crucial for cancer cell growth. However, the mechanism of how proteasome activity is maintained in cancer cells has remained unclear. The CNC family transcription factor NFE2L1 induces the expression of almost all proteasome-related genes under proteasome inhibition. Both and its phylogenetically closest homolog, , are highly expressed in several types of cancer, such as colorectal cancer. Here, we demonstrate that NFE2L1 and NFE2L3 complementarily maintain basal proteasome activity in cancer cells. Double knockdown of and impaired basal proteasome activity in cancer cells and cancer cell resistance to a proteasome inhibitor anticancer drug, bortezomib, by significantly reducing the basal expression of seven proteasome-related genes: , , , , , , and Interestingly, the molecular basis behind these cellular consequences was that NFE2L3 repressed NFE2L1 translation by the induction of the gene encoding the translational regulator CPEB3, which binds to the 3' untranslated region and decreases polysome formation on mRNA. Consistent results were obtained from clinical analysis, wherein patients with cancer having tumors expressing higher levels of / exhibit poor prognosis. These results provide the novel regulatory mechanism of basal proteasome activity in cancer cells through an NFE2L3-CPEB3-NFE2L1 translational repression axis.

Citing Articles

New insight into the CNC-bZIP member, NFE2L3, in human diseases.

Xiong G, Li J, Yao F, Yang F, Xiang Y Front Cell Dev Biol. 2024; 12:1430486.

PMID: 39149514 PMC: 11325725. DOI: 10.3389/fcell.2024.1430486.

Ferroptosis regulation by Cap'n'collar family transcription factors.

Murray M, Dixon S J Biol Chem. 2024; 300(8):107583.

PMID: 39025451 PMC: 11387702. DOI: 10.1016/j.jbc.2024.107583.

Early recovery of proteasome activity in cells pulse-treated with proteasome inhibitors is independent of DDI2.

Ibtisam I, Kisselev A Elife. 2024; 12.

PMID: 38619391 PMC: 11018354. DOI: 10.7554/eLife.91678.

Metformin suppresses NFE2L1 pathway activation to inhibit gap junction beta protein expression in NSCLC.

Yu S, Ren H, Liu T, Han X, Guo H, Ning Q Cancer Med. 2024; 13(7):e7021.

PMID: 38562019 PMC: 10985411. DOI: 10.1002/cam4.7021.

Identification roles of NFE2L3 in digestive system cancers.

Li F, Wen Z J Cancer Res Clin Oncol. 2024; 150(3):150.

PMID: 38514488 PMC: 10957624. DOI: 10.1007/s00432-024-05656-y.

References

Koizumi S, Irie T, Hirayama S, Sakurai Y, Yashiroda H, Naguro I . The aspartyl protease DDI2 activates Nrf1 to compensate for proteasome dysfunction. Elife. 2016; 5. PMC: 5001836. DOI: 10.7554/eLife.18357. View

Wang H, Zhan M, Yang R, Shi Y, Liu Q, Wang J . Elevated expression of NFE2L3 predicts the poor prognosis of pancreatic cancer patients. Cell Cycle. 2018; 17(17):2164-2174. PMC: 6226237. DOI: 10.1080/15384101.2018.1520558. View

Liu Y, Sethi N, Hinoue T, Schneider B, Cherniack A, Sanchez-Vega F . Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. Cancer Cell. 2018; 33(4):721-735.e8. PMC: 5966039. DOI: 10.1016/j.ccell.2018.03.010. View

Hodgman R, Tay J, Mendez R, Richter J . CPEB phosphorylation and cytoplasmic polyadenylation are catalyzed by the kinase IAK1/Eg2 in maturing mouse oocytes. Development. 2001; 128(14):2815-22. DOI: 10.1242/dev.128.14.2815. View

Tsuchiya Y, Taniguchi H, Ito Y, Morita T, Karim M, Ohtake N . The casein kinase 2-nrf1 axis controls the clearance of ubiquitinated proteins by regulating proteasome gene expression. Mol Cell Biol. 2013; 33(17):3461-72. PMC: 3753846. DOI: 10.1128/MCB.01271-12. View

Murata S, Udono H, Tanahashi N, Hamada N, Watanabe K, Adachi K . Immunoproteasome assembly and antigen presentation in mice lacking both PA28alpha and PA28beta. EMBO J. 2001; 20(21):5898-907. PMC: 125708. DOI: 10.1093/emboj/20.21.5898. View

Mendez R, Richter J . Translational control by CPEB: a means to the end. Nat Rev Mol Cell Biol. 2001; 2(7):521-9. DOI: 10.1038/35080081. View

Radhakrishnan S, Lee C, Young P, Beskow A, Chan J, Deshaies R . Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells. Mol Cell. 2010; 38(1):17-28. PMC: 2874685. DOI: 10.1016/j.molcel.2010.02.029. View

Loda M, Cukor B, Tam S, Lavin P, Fiorentino M, Draetta G . Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med. 1997; 3(2):231-4. DOI: 10.1038/nm0297-231. View

10.

Manasanch E, Orlowski R . Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol. 2017; 14(7):417-433. PMC: 5828026. DOI: 10.1038/nrclinonc.2016.206. View

11.

Sha Z, Goldberg A . Proteasome-mediated processing of Nrf1 is essential for coordinate induction of all proteasome subunits and p97. Curr Biol. 2014; 24(14):1573-1583. PMC: 4108618. DOI: 10.1016/j.cub.2014.06.004. View

12.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

13.

Bury M, Le Calve B, Lessard F, Dal Maso T, Saliba J, Michiels C . NFE2L3 Controls Colon Cancer Cell Growth through Regulation of DUX4, a CDK1 Inhibitor. Cell Rep. 2019; 29(6):1469-1481.e9. DOI: 10.1016/j.celrep.2019.09.087. View

14.

Afroz T, Skrisovska L, Belloc E, Guillen-Boixet J, Mendez R, Allain F . A fly trap mechanism provides sequence-specific RNA recognition by CPEB proteins. Genes Dev. 2014; 28(13):1498-514. PMC: 4083092. DOI: 10.1101/gad.241133.114. View

15.

Huang Y, Kan M, Lin C, Richter J . CPEB3 and CPEB4 in neurons: analysis of RNA-binding specificity and translational control of AMPA receptor GluR2 mRNA. EMBO J. 2006; 25(20):4865-76. PMC: 1618119. DOI: 10.1038/sj.emboj.7601322. View

16.

Chowdhury A, Katoh H, Hatanaka A, Iwanari H, Nakamura N, Hamakubo T . Multiple regulatory mechanisms of the biological function of NRF3 (NFE2L3) control cancer cell proliferation. Sci Rep. 2017; 7(1):12494. PMC: 5624902. DOI: 10.1038/s41598-017-12675-y. View

17.

Luo J, Solimini N, Elledge S . Principles of cancer therapy: oncogene and non-oncogene addiction. Cell. 2009; 136(5):823-37. PMC: 2894612. DOI: 10.1016/j.cell.2009.02.024. View

18.

Fernandez-Miranda G, Mendez R . The CPEB-family of proteins, translational control in senescence and cancer. Ageing Res Rev. 2012; 11(4):460-72. DOI: 10.1016/j.arr.2012.03.004. View

19.

Lee C, Lee C, Hu T, Nguyen J, Zhang J, Martin M . Loss of nuclear factor E2-related factor 1 in the brain leads to dysregulation of proteasome gene expression and neurodegeneration. Proc Natl Acad Sci U S A. 2011; 108(20):8408-13. PMC: 3100960. DOI: 10.1073/pnas.1019209108. View

20.

Adams J . The development of proteasome inhibitors as anticancer drugs. Cancer Cell. 2004; 5(5):417-21. DOI: 10.1016/s1535-6108(04)00120-5. View